Skip to content
Conference Open access

Upstream and Downstream Convergence: How do the GBA1 and LRRK2 genes disrupt PINK1/Parkin-Mediated Mitophagy?

Oct 2026 · Proceedings of the OJSS Virtual Research Conference 2026 · 0 citations

TL;DR

A convergence model is established, where GBA1 and LRRK2 mutations disrupt different checkpoints of the PINK1/Parkin mitophagy axis, but converge on the common collapse of mitochondrial quality control that creates both genotype-specific and shared therapeutic targets in PD.

Abstract

Parkinson’s Disease (PD) is a complex progressive neurodegenerative disease with certain cases exhibiting non-idiopathic forms. Understanding this allows for a better understanding about the disease and treatment options. The 2 main genetic forms of PD are mutations in the Glucosylceramidase Beta 1 (GBA1) and Leucine-Rich Repeat Kinase 2 (LRRK2) genes. GBA1 and LRRK2 gene mutations disrupt mitophagy through distinct mechanisms that converge on PINK1/Parkin-linked mitochondrial quality control in PD. GBA1 mutations impair lysosomal enzyme glucocerebrosidase (GCase), causing toxic substance accumulation and an aggressive phenotype of early motor declining and severe non-motor symptoms. Pathogenic LRRK2 mutations induce a toxic gain of function by hyperactivating kinase activity, significantly increasing phosphorylation of downstream Rab GTPases and disrupting vital endolysosomal trafficking. This impairs mitophagy and clearance of misfolded proteins, ultimately driving neurodegeneration of dopaminergic neurons. While standard scientific literature traditionally examines these genetic pathways in isolation, they can synergistically disrupt mitophagy and lysosomal pathways causing PD. A joint review is also critical especially as dual-inhibitor clinical trials emerge and multi-mutation carriers present uniquely altered phenotypes. This review establishes a convergence model, where GBA1 and LRRK2 mutations disrupt different checkpoints of the PINK1/Parkin mitophagy axis, but converge on the common collapse of mitochondrial quality control that creates both genotype-specific and shared therapeutic targets.

Read PDF

Similar papers

Open access Nov 2026

Pharmaco-genetic evidence of presymptomatic lysosomal dysfunction coupled to detrimental DPR secretion in Drosophila Models of C9orf72-linked ALS/FTD

Hexanucleotide repeat expansions in C9orf72, the most common genetic cause of Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), drive neurodegeneration through both loss of gene function and toxic gain-of-function mechanisms, including transcription of repeat RNA and repeat-associated non-AUG (RAN)...

Paulien H. Smeele, V. Ferrari, Giorgia Spina et al. · 0 citations
Review Oct 2026

The Mechanism of the Parkin-CMA-NLRP3-PANoptosis Signaling Axis in Parkinson's Disease: From Molecular Basis to Therapeutic Strategies.

A systematic review systematically delineates the molecular framework of the Parkin‑CMA‑NLRP3‑PANoptosis signaling axis and summarizes translational progress of small‑molecule compounds and gene therapies targeting individual components within this cascade.

Xing-Hua Tian, Biao Zhang, Yu Wang et al. · 0 citations
Open access Sep 2026

PPM1H loss alters intrasynaptic alpha-synuclein localization in a LRRK2-dependent manner

Mutations in the LRRK2 gene are a major genetic cause of Parkinson’s disease (PD) and induce hyperphosphorylation of RAB GTPases through increased LRRK2 kinase activity. The phosphatase PPM1H counteracts this activity by selectively dephosphorylating LRRK2-phosphorylated RAB proteins. Here, we used primary PPM1H knocko...

L. Evers, Jessica M. Grein, C. A. Boecker · 0 citations
Review Oct 2026

A critical mechanistic synthesis of PINK1-mediated mitophagy signaling and its therapeutic targeting in Parkinson's disease neurodegeneration.

It is found that PD is a biologically and clinically heterogeneous disease that requires biomarker-directed and genotype-stratified therapeutic development and major translational issues are critically evaluated, including challenges related to blood-brain barrier penetration, target specificity, and long-term safety o...

Abid Khan, T. Jawaid, Z. Urrehman et al. · 0 citations
Open access Oct 2026

Parkin deficiency rewires the genetic dependencies that govern neuronal survival

It is found that Parkin loss also rewires the genetic dependencies that govern neuronal survival, which changes which genes neurons require to survive, so phenotypes read as deficits may instead mark altered requirements, and genotype may determine whether an intervention helps or harms.

Shi-Jie Wang, Daniel R. Gulbranson, Beatrice Costa et al. · 0 citations
Open access Nov 2026

LRRK2 G2019S Parkinson’s Disease Mutation and Astrocyte–Neuron Crosstalk: How Diseased Astrocytes Program the Susceptibility to Inflammation and Oxidative Stress Predisposing to Nigrostriatal Degeneration

A complex interplay between genes and environmental factors is recognized to contribute to dopaminergic neuron death in Parkinson’s disease (PD). Within the known genes associated with PD, there is Leucine-Rich Repeat Kinase (LRRK2), known as one of the most frequent causes of PD, of either familial or sporadic nature....

B. Marchetti, M. F. Serapide · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.